SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP is investigating potential claims against ARS Pharmaceuticals Inc. ("ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark.

On June 24, 2026, after the market closed, ARS published a press release announcing that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle, and that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, ARS's stock price fell $2.52, or 23.9%, to close at $8.02 per share on June 25, 2026, on unusually heavy trading volume.